Lessons From Ebola: FDA Floats New Paradigm For Testing Drugs In Emergencies
This article was originally published in The Pink Sheet Daily
Executive Summary
Adaptive, randomized trial design could be model for therapies aimed at other emerging diseases, such as MERS-CoV, officials write in New England Journal of Medicine.